既往吸烟暴露和慢性阻塞性肺疾病合并症对重度哮喘患者单克隆抗体治疗反应的影响。
Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma.
作者信息
Morobeid Heba, Pizarro Carmen, Biener Leonie, Ulrich-Merzenich Gudrun, Kütting Daniel, Nickenig Georg, Skowasch Dirk
机构信息
Dept of Internal Medicine II - Pneumology/Cardiology, University Hospital Bonn, Bonn, Germany.
These authors contributed equally.
出版信息
ERJ Open Res. 2021 Aug 16;7(3). doi: 10.1183/23120541.00190-2021. eCollection 2021 Jul.
Abstract
摘要
https://bit.ly/3fYC8tC. （此为链接，无法准确翻译其内容，保留原文链接形式）
相似文献
1
Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma.既往吸烟暴露和慢性阻塞性肺疾病合并症对重度哮喘患者单克隆抗体治疗反应的影响。
ERJ Open Res. 2021 Aug 16;7(3). doi: 10.1183/23120541.00190-2021. eCollection 2021 Jul.
2
Consistency and reliability of smoking-related variables: longitudinal study design in asthma and COPD.吸烟相关变量的一致性和可靠性：哮喘与慢性阻塞性肺疾病的纵向研究设计
Eur Clin Respir J. 2019 Apr 11;6(1):1591842. doi: 10.1080/20018525.2019.1591842. eCollection 2019.
3
Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA).西班牙慢性阻塞性肺疾病指南（GesEPOC）与西班牙哮喘管理指南（GEMA）关于哮喘-慢性阻塞性肺疾病重叠综合征（ACOS）的共识。
Arch Bronconeumol. 2017 Aug;53(8):443-449. doi: 10.1016/j.arbres.2017.04.002. Epub 2017 May 8.
4
Bronchial mucosal dendritic cells in smokers and ex-smokers with COPD: an electron microscopic study.慢性阻塞性肺疾病吸烟者和戒烟者的支气管黏膜树突状细胞：一项电子显微镜研究
Thorax. 2008 Feb;63(2):108-14. doi: 10.1136/thx.2007.078253. Epub 2007 Sep 17.
5
Comparative prevalence of co-morbidities in smoking and non-smoking asthma patients with incomplete reversibility of airway obstruction, non-smoking asthma patients with complete reversibility of airway obstruction and COPD patients.气道阻塞不完全可逆的吸烟和非吸烟哮喘患者、气道阻塞完全可逆的非吸烟哮喘患者以及慢性阻塞性肺疾病（COPD）患者中合并症的比较患病率。
Respir Med. 2017 Apr;125:82-88. doi: 10.1016/j.rmed.2017.03.005. Epub 2017 Mar 6.
6
The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?英国首次新冠疫情高峰对重度哮喘患者的影响。哪个更糟糕：病毒还是封锁措施？
ERJ Open Res. 2021 Feb 1;7(1). doi: 10.1183/23120541.00768-2020. eCollection 2021 Jan.
7
Asthma and smoking-induced airway disease without spirometric COPD.哮喘和吸烟引起的气道疾病，无 spirometric COPD。
Eur Respir J. 2017 May 1;49(5). doi: 10.1183/13993003.02061-2016. Print 2017 May.
8
Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit.意大利成年人哮喘和 COPD：考虑吸烟习惯的 BMI 作用。
Respir Med. 2013 Sep;107(9):1417-22. doi: 10.1016/j.rmed.2013.04.021. Epub 2013 May 20.
9
The effect of pulmonary rehabilitation on smoking and health outcomes in COPD patients.肺康复对 COPD 患者吸烟和健康结局的影响。
Clin Respir J. 2021 Aug;15(8):855-862. doi: 10.1111/crj.13373. Epub 2021 Apr 23.
10
Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States.美国哮喘/慢性阻塞性肺疾病重叠的特征与患病率
Ann Am Thorac Soc. 2016 Jun;13(6):803-10. doi: 10.1513/AnnalsATS.201508-554OC.
引用本文的文献
1
Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study.tezepelumab在美国不同严重哮喘患者群体中的有效性和安全性：PASSAGE研究的初步结果
Adv Ther. 2025 Jul;42(7):3334-3353. doi: 10.1007/s12325-025-03231-6. Epub 2025 May 19.
2
The Influence of Emphysema on Treatment Response to Biologic Therapy in Severe Asthma.肺气肿对重度哮喘生物治疗反应的影响。
J Asthma Allergy. 2024 Nov 8;17:1129-1140. doi: 10.2147/JAA.S474306. eCollection 2024.
3
Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study).德国哮喘网络严重哮喘登记处使用美泊利单抗的真实世界经验（MepoGAN研究）。
J Asthma Allergy. 2023 May 11;16:541-552. doi: 10.2147/JAA.S403286. eCollection 2023.
4
Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD.在重度嗜酸性粒细胞性哮喘和慢性阻塞性肺疾病患者中使用白细胞介素（IL）-5/IL-5受体抗体进行治疗。
ERJ Open Res. 2022 Oct 24;8(4). doi: 10.1183/23120541.00207-2022. eCollection 2022 Oct.
5
Asthma and Tobacco Smoking.哮喘与吸烟
J Pers Med. 2022 Jul 27;12(8):1231. doi: 10.3390/jpm12081231.
本文引用的文献
1
Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.奥马珠单抗治疗重度过敏性哮喘的真实世界疗效：一项观察性研究的荟萃分析。
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2702-2714. doi: 10.1016/j.jaip.2021.01.011. Epub 2021 Jan 21.
2
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.贝那鲁肽在重度嗜酸性哮喘中的真实世界疗效。
Chest. 2021 Feb;159(2):496-506. doi: 10.1016/j.chest.2020.08.2083. Epub 2020 Aug 31.
3
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.真实世界中美泊利单抗在前瞻性重度哮喘 REALITI-A 研究中的应用：初步分析。
Eur Respir J. 2020 Oct 15;56(4). doi: 10.1183/13993003.00151-2020. Print 2020 Oct.
4
Comparison of Artificial Intelligence-Based Fully Automatic Chest CT Emphysema Quantification to Pulmonary Function Testing.基于人工智能的全自动 CT 肺气肿定量与肺功能测试的比较。
AJR Am J Roentgenol. 2020 May;214(5):1065-1071. doi: 10.2214/AJR.19.21572. Epub 2020 Mar 4.
5
Protocol of a Randomized Controlled Study of the PneumRx Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema (ELEVATE).随机对照研究方案：PneumRx 支气管内线圈系统与标准医疗管理治疗严重肺气肿患者的对照（ELEVATE）。
Respiration. 2019;98(6):512-520. doi: 10.1159/000502100. Epub 2019 Nov 19.
6
Characteristics and treatment regimens across ERS SHARP severe asthma registries.欧洲呼吸学会严重哮喘注册研究中的特征及治疗方案
Eur Respir J. 2020 Jan 9;55(1). doi: 10.1183/13993003.01163-2019. Print 2020 Jan.
7
Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.抗白细胞介素-5 疗法在严重嗜酸性粒细胞性哮喘患者中的临床疗效及可能的治疗反应标准。
BMC Pulm Med. 2018 Jul 18;18(1):119. doi: 10.1186/s12890-018-0689-2.
8
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.度普利尤单抗在中重度未控制哮喘中的疗效和安全性。
N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.
9
Asthma and smoking-induced airway disease without spirometric COPD.哮喘和吸烟引起的气道疾病，无 spirometric COPD。
Eur Respir J. 2017 May 1;49(5). doi: 10.1183/13993003.02061-2016. Print 2017 May.
10
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.贝那鲁肽治疗高剂量吸入性皮质激素和长效β-agonists 控制不佳的严重哮喘患者的疗效和安全性（SIROCCO）：一项随机、多中心、安慰剂对照的 3 期临床试验。
Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5.
Zotero 插件